BNP Paribas Financial Markets Sells 859 Shares of LENZ Therapeutics, Inc. (NASDAQ:LENZ)

BNP Paribas Financial Markets trimmed its position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) by 32.4% during the fourth quarter, according to its most recent 13F filing with the SEC. The fund owned 1,789 shares of the company’s stock after selling 859 shares during the period. BNP Paribas Financial Markets’ holdings in LENZ Therapeutics were worth $52,000 as of its most recent filing with the SEC.

A number of other hedge funds have also recently bought and sold shares of LENZ. Mirae Asset Global Investments Co. Ltd. bought a new position in LENZ Therapeutics in the 4th quarter valued at $29,000. KLP Kapitalforvaltning AS bought a new position in LENZ Therapeutics in the 4th quarter valued at $46,000. Tower Research Capital LLC TRC boosted its position in LENZ Therapeutics by 162.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 1,860 shares of the company’s stock valued at $54,000 after buying an additional 1,151 shares during the last quarter. Virtus ETF Advisers LLC bought a new position in LENZ Therapeutics in the 4th quarter valued at $67,000. Finally, SG Americas Securities LLC boosted its position in LENZ Therapeutics by 20.7% in the 4th quarter. SG Americas Securities LLC now owns 5,458 shares of the company’s stock valued at $158,000 after buying an additional 935 shares during the last quarter. 54.32% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

LENZ has been the topic of several recent research reports. HC Wainwright restated a “buy” rating and issued a $38.00 price target on shares of LENZ Therapeutics in a research report on Thursday, May 8th. TD Cowen initiated coverage on LENZ Therapeutics in a research report on Tuesday, March 18th. They issued a “buy” rating and a $60.00 price target on the stock. Piper Sandler initiated coverage on LENZ Therapeutics in a research report on Monday, April 14th. They issued an “overweight” rating and a $51.00 price target on the stock. Finally, Citigroup raised their price target on LENZ Therapeutics from $44.00 to $47.00 and gave the stock a “buy” rating in a research report on Thursday, March 20th. Five equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $46.60.

LENZ Therapeutics Trading Up 2.1%

Shares of LENZ Therapeutics stock opened at $29.77 on Wednesday. The stock’s fifty day simple moving average is $25.85 and its 200 day simple moving average is $27.02. LENZ Therapeutics, Inc. has a 12 month low of $14.42 and a 12 month high of $38.93. The company has a market capitalization of $837.91 million, a PE ratio of -16.82 and a beta of 0.41.

LENZ Therapeutics (NASDAQ:LENZ) last released its quarterly earnings results on Wednesday, May 7th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.55) by $0.02. Analysts predict that LENZ Therapeutics, Inc. will post -2.18 EPS for the current fiscal year.

About LENZ Therapeutics

LENZ Therapeutics, Inc, a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.